• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在纳入动物数据的 I 期肿瘤学试验中,跨越患者亚组。

Bridging across patient subgroups in phase I oncology trials that incorporate animal data.

机构信息

Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.

Department of Mathematics and Statistics, Lancaster University, Lancashire, UK.

出版信息

Stat Methods Med Res. 2021 Apr;30(4):1057-1071. doi: 10.1177/0962280220986580. Epub 2021 Jan 27.

DOI:10.1177/0962280220986580
PMID:33501882
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8129464/
Abstract

In this paper, we develop a general Bayesian hierarchical model for bridging across patient subgroups in phase I oncology trials, for which preliminary information about the dose-toxicity relationship can be drawn from animal studies. Parameters that re-scale the doses to adjust for intrinsic differences in toxicity, either between animals and humans or between human subgroups, are introduced to each dose-toxicity model. Appropriate priors are specified for these scaling parameters, which capture the magnitude of uncertainty surrounding the animal-to-human translation and bridging assumption. After mapping data onto a common, 'average' human dosing scale, human dose-toxicity parameters are assumed to be exchangeable either with the standardised, animal study-specific parameters, or between themselves across human subgroups. Random-effects distributions are distinguished by different covariance matrices that reflect the between-study heterogeneity in animals and humans. Possibility of non-exchangeability is allowed to avoid inferences for extreme subgroups being overly influenced by their complementary data. We illustrate the proposed approach with hypothetical examples, and use simulation to compare the operating characteristics of trials analysed using our Bayesian model with several alternatives. Numerical results show that the proposed approach yields robust inferences, even when data from multiple sources are inconsistent and/or the bridging assumptions are incorrect.

摘要

在本文中,我们开发了一种通用的贝叶斯分层模型,用于在肿瘤学 I 期临床试验中跨越患者亚组,对于这些临床试验,可以从动物研究中获得关于剂量-毒性关系的初步信息。我们为每个剂量-毒性模型引入了参数,这些参数可以重新调整剂量,以调整毒性在动物和人类之间或人类亚组之间的内在差异。为这些缩放参数指定了适当的先验,这些参数捕捉了围绕动物到人类转化和桥接假设的不确定性的大小。在将数据映射到共同的“平均”人类剂量尺度之后,假设人类剂量-毒性参数可以与标准化的、特定于动物研究的参数交换,或者在人类亚组之间相互交换。随机效应分布通过不同的协方差矩阵来区分,这些协方差矩阵反映了动物和人类之间的研究间异质性。允许非可交换性的存在,以避免对极端亚组的推断受到其互补数据的过度影响。我们通过假设示例来说明所提出的方法,并使用模拟来比较使用我们的贝叶斯模型分析的试验与几种替代方法的操作特征。数值结果表明,即使来自多个来源的数据不一致和/或桥接假设不正确,所提出的方法也能得出稳健的推断。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b69/8129464/931f6d698d46/10.1177_0962280220986580-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b69/8129464/1c5624e1955c/10.1177_0962280220986580-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b69/8129464/528b7461dd49/10.1177_0962280220986580-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b69/8129464/cc08987eb582/10.1177_0962280220986580-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b69/8129464/e56f6f37439c/10.1177_0962280220986580-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b69/8129464/931f6d698d46/10.1177_0962280220986580-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b69/8129464/1c5624e1955c/10.1177_0962280220986580-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b69/8129464/528b7461dd49/10.1177_0962280220986580-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b69/8129464/cc08987eb582/10.1177_0962280220986580-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b69/8129464/e56f6f37439c/10.1177_0962280220986580-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b69/8129464/931f6d698d46/10.1177_0962280220986580-fig5.jpg

相似文献

1
Bridging across patient subgroups in phase I oncology trials that incorporate animal data.在纳入动物数据的 I 期肿瘤学试验中,跨越患者亚组。
Stat Methods Med Res. 2021 Apr;30(4):1057-1071. doi: 10.1177/0962280220986580. Epub 2021 Jan 27.
2
A robust Bayesian meta-analytic approach to incorporate animal data into phase I oncology trials.一种稳健的贝叶斯荟萃分析方法,用于将动物数据纳入肿瘤 I 期临床试验。
Stat Methods Med Res. 2020 Jan;29(1):94-110. doi: 10.1177/0962280218820040. Epub 2019 Jan 16.
3
Subgroup-specific dose finding for phase I-II trials using Bayesian clustering.基于贝叶斯聚类的 I/II 期临床试验亚组特异性剂量探索。
Stat Med. 2022 Jul 20;41(16):3164-3179. doi: 10.1002/sim.9410. Epub 2022 Apr 16.
4
A Bayesian adaptive design for dual-agent phase I-II oncology trials integrating efficacy data across stages.一种贝叶斯自适应设计,用于整合各阶段疗效数据的双药物 I/II 期肿瘤学试验。
Biom J. 2023 Oct;65(7):e2200288. doi: 10.1002/bimj.202200288. Epub 2023 May 18.
5
Bayesian Semi-parametric Design (BSD) for adaptive dose-finding with multiple strata.贝叶斯半参数设计(BSD)用于具有多个层的自适应剂量发现。
J Biopharm Stat. 2020 Sep 2;30(5):806-820. doi: 10.1080/10543406.2020.1730870. Epub 2020 Mar 4.
6
Bayesian designs of phase II oncology trials to select maximum effective dose assuming monotonic dose-response relationship.在假设剂量反应关系单调的情况下,用于选择最大有效剂量的II期肿瘤试验的贝叶斯设计。
BMC Med Res Methodol. 2014 Jul 29;14:95. doi: 10.1186/1471-2288-14-95.
7
A Bayesian decision-theoretic approach to incorporate preclinical information into phase I oncology trials.贝叶斯决策理论在肿瘤 I 期临床试验中纳入临床前信息的应用。
Biom J. 2020 Oct;62(6):1408-1427. doi: 10.1002/bimj.201900161. Epub 2020 Apr 13.
8
A simulation study of methods for selecting subgroup-specific doses in phase 1 trials.1期试验中选择亚组特异性剂量方法的模拟研究。
Pharm Stat. 2017 Mar;16(2):143-156. doi: 10.1002/pst.1797. Epub 2017 Jan 23.
9
Comparing Bayesian hierarchical meta-regression methods and evaluating the influence of priors for evaluations of surrogate endpoints on heterogeneous collections of clinical trials.比较贝叶斯分层元回归方法并评估先验信息对异质性临床试验集合中替代终点评估的影响。
BMC Med Res Methodol. 2024 Feb 16;24(1):39. doi: 10.1186/s12874-024-02170-0.
10
Two-stage subgroup-specific time-to-event (2S-Sub-TITE): An adaptive two-stage time-to-toxicity design for subgroup-specific dose finding in phase I oncology trials.两阶段亚组特定时间事件(2S-Sub-TITE):一种适应性两阶段时间毒性设计,用于肿瘤 I 期临床试验中针对亚组特定剂量的发现。
Pharm Stat. 2022 Nov;21(6):1138-1148. doi: 10.1002/pst.2231. Epub 2022 May 12.

引用本文的文献

1
A Bayesian approach to pilot-pivotal trials for bioequivalence assessment.一种用于生物等效性评估的先导关键性试验的贝叶斯方法。
BMC Med Res Methodol. 2023 Dec 19;23(1):301. doi: 10.1186/s12874-023-02120-2.
2
A Bayesian adaptive design for dual-agent phase I-II oncology trials integrating efficacy data across stages.一种贝叶斯自适应设计,用于整合各阶段疗效数据的双药物 I/II 期肿瘤学试验。
Biom J. 2023 Oct;65(7):e2200288. doi: 10.1002/bimj.202200288. Epub 2023 May 18.

本文引用的文献

1
Borrowing of information across patient subgroups in a basket trial based on distributional discrepancy.基于分布差异的篮子试验中患者亚组间信息的借用。
Biostatistics. 2022 Jan 13;23(1):120-135. doi: 10.1093/biostatistics/kxaa019.
2
A Bayesian decision-theoretic approach to incorporate preclinical information into phase I oncology trials.贝叶斯决策理论在肿瘤 I 期临床试验中纳入临床前信息的应用。
Biom J. 2020 Oct;62(6):1408-1427. doi: 10.1002/bimj.201900161. Epub 2020 Apr 13.
3
A robust Bayesian meta-analytic approach to incorporate animal data into phase I oncology trials.
一种稳健的贝叶斯荟萃分析方法,用于将动物数据纳入肿瘤 I 期临床试验。
Stat Methods Med Res. 2020 Jan;29(1):94-110. doi: 10.1177/0962280218820040. Epub 2019 Jan 16.
4
Exploring Ethnic Differences in Toxicity in Early-Phase Clinical Trials for Oncology Drugs.探索肿瘤药物早期临床试验中毒性的种族差异。
Ther Innov Regul Sci. 2014 Sep;48(5):644-650. doi: 10.1177/2168479014524582.
5
Dose-escalation strategies which use subgroup information.使用亚组信息的剂量递增策略。
Pharm Stat. 2018 Sep;17(5):414-436. doi: 10.1002/pst.1860. Epub 2018 Jun 13.
6
A Bayesian basket trial design using a calibrated Bayesian hierarchical model.一种使用校准贝叶斯分层模型的贝叶斯篮子试验设计。
Clin Trials. 2018 Apr;15(2):149-158. doi: 10.1177/1740774518755122. Epub 2018 Mar 2.
7
Bayesian dose-finding phase I trial design incorporating historical data from a preceding trial.纳入先前试验历史数据的贝叶斯剂量探索I期试验设计。
Pharm Stat. 2018 Jul;17(4):372-382. doi: 10.1002/pst.1850. Epub 2018 Jan 25.
8
Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both.用于研究多种疗法、多种疾病或两者兼有的主方案。
N Engl J Med. 2017 Jul 6;377(1):62-70. doi: 10.1056/NEJMra1510062.
9
Bridging data across studies using frequentist and Bayesian estimation.使用频率论和贝叶斯估计跨研究桥接数据。
J Biopharm Stat. 2017;27(3):426-441. doi: 10.1080/10543406.2017.1289948. Epub 2017 Feb 7.
10
Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples.临床研究中的统计学争议:篮子试验、伞式试验和其他主方案:综述和实例。
Ann Oncol. 2017 Jan 1;28(1):34-43. doi: 10.1093/annonc/mdw413.